Abstract

Application of NGS in Personalized Oncology – From Discovery to Clinical Application

Ong Choon Kiat, Senior Scientist, National Cancer Centre Singapore

With landmark mutation studies for each cancer type completed and the reduced cost in high throughput sequencing, the pace toward personalized oncology is gaining momentum. I will be describing the use of NGS for discovery and how this information is translated to clinical applications. The discovery process will be illustrated by our recently works in cholangiocarcinoma (CCA), NK/T-cell lymphoma (NKTCL) and upper urinary tract urothelial cancer (UUTUC). The clinical applications will be highlighted using the discoveries made for each of these different cancers. For examples, CCA patient harbouring IDH1/2 activating mutation might response to the recently identified IDH1 and IDH2 inhibitors. NKTCL patient harbouring activating Jak3 mutation might response to FDA approved pan-JAK inhibitors. The potential use of the mutation signature in aristolochic acid-induced UUTUC to identify cancer patient’s exposure to this group I carcinogen. I will also describe the application of exome and RNA sequencing in one case of lung cancer and some of the challenges faced using these massive amounts of information.